8-K:重大事件
10-Q:季度报表
8-K:Citius Pharmicals, Inc. 公布2024财年第二季度财务业绩并提供业务最新情况
SC 13G/A:超过5%持股股东披露文件(修正)-BlackRock, Inc.(4.8%)
8-K:重大事件
424B5:募资说明书
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | 4:持股变动声明-高管 HOLUBIAK MYRON Z
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | 8-K:重大事件
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | 4:持股变动声明-高管 Mazur Leonard L
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | 4:持股变动声明-董事 Smith Robert Joseph
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | 8-K:重大事件
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | 3:首次持股声明-董事 Smith Robert Joseph
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | 8-K:重大事件
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | EFFECT:其他
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | UPLOAD:其他
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | CORRESP:信函
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | S-3:特定交易注册声明
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | S-8:员工福利计划证券登记
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | 8-K:Citius Pharmicals, Inc. 公布2024财年第一季度财务业绩并提供业务最新情况
Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) | 10-Q:季度报表
暂无数据